What is the difference between Hepatitis B and Hepatitis C?

Hepatitis B is a DNA virus transmitted through blood, semen, or other body fluids, while Hepatitis C is an RNA virus spread primarily through blood-to-blood contact, with both targeting the liver but differing in chronic infection rates and treatment approaches.

Which is worse, Hepatitis B or Hepatitis C?

Hepatitis C is generally considered more severe in its chronic form because it leads to cirrhosis or liver cancer in up to 25% of infected individuals, whereas Hepatitis B has a higher rate of spontaneous clearance in adults, though both can cause fatal liver damage.

Is Hepatitis C more curable than Hepatitis B?

Yes, Hepatitis C is now curable in over 95% of cases with direct-acting antiviral medications taken for 8-12 weeks, while Hepatitis B has no complete cure and requires long-term antiviral therapy to suppress the virus and prevent liver complications.

What is the cost difference between Hepatitis B and Hepatitis C treatment?

Hepatitis B treatment costs roughly $500 to $2,000 per month for lifelong antiviral pills, whereas Hepatitis C curative therapy ranges from $24,000 to $94,000 for a full course, though generic versions have reduced prices to under $1,000 in some countries.

Which is more contagious, Hepatitis B or Hepatitis C?

Hepatitis B is 50 to 100 times more infectious than Hepatitis C because it survives outside the body for up to seven days and transmits easily through sexual contact, needle sharing, or from mother to baby, whereas Hepatitis C requires direct blood exposure and is rarely sexually transmitted.

Can you have both Hepatitis B and Hepatitis C at the same time?

Yes, co-infection with both Hepatitis B and Hepatitis C occurs in about 5-10% of people with chronic viral hepatitis, and this combination accelerates liver damage, increases cirrhosis risk, and requires careful treatment sequencing to avoid viral reactivation.

Is Hepatitis B or Hepatitis C more common in the United States?

Hepatitis C is more common in the United States, with an estimated 2.4 million people living with chronic infection versus 0.8 to 1.0 million with chronic Hepatitis B, though Hepatitis B rates are higher among Asian-American and immigrant populations.

Can Hepatitis B be treated the same way as Hepatitis C?

No, Hepatitis B requires nucleoside analogs like tenofovir or entecavir to suppress viral replication indefinitely, while Hepatitis C uses interferon-free direct-acting antivirals that eradicate the virus, so the two diseases need completely different medication regimens and monitoring schedules.

What is the survival rate for Hepatitis B compared to Hepatitis C?

Untreated Hepatitis B has a 15-25% risk of dying from cirrhosis or liver cancer over decades, while untreated Hepatitis C carries a similar 15-30% mortality risk, but with modern treatments, Hepatitis C patients achieve normal life expectancy whereas Hepatitis B patients still face ongoing surveillance needs.

Can I switch from Hepatitis B treatment to Hepatitis C treatment?

No, you cannot switch between these treatments because they target different viruses, and using Hepatitis C drugs for Hepatitis B is ineffective, so you must complete your Hepatitis B antiviral regimen and only consider Hepatitis C therapy if you have a confirmed co-infection with that specific virus.

Difference Between

Difference Between Hepatitis B and C

Written byNex Virox Team

Editorial Team

Reviewed byVarshal Nirbhavane

Senior SEO & Organic Growth Professional · 5+ years

Published: September 9, 202620 min read

Quick answer

The main difference between Hepatitis B and C is that Hepatitis B is a DNA virus transmitted primarily through blood, sexual contact, or from mother to child, while Hepatitis C is an RNA virus spread mainly through blood-to-blood contact. Hepatitis B is a vaccine-preventable liver infection, while C is a curable liver infection without a vaccine.

Key takeaways

Core distinction: Hepatitis B is a DNA virus transmitted via blood or bodily fluids, while Hepatitis C is an RNA virus spread mainly through blood-to-blood contact.
Chronic infection rates: About 90% of infants with Hepatitis B develop chronic infection, whereas roughly 75-85% of Hepatitis C cases become chronic in adults.
Treatment approaches: Hepatitis B uses antiviral pills like tenofovir to suppress viral replication, but Hepatitis C is curable with 8-12 weeks of direct-acting antivirals.
Vaccine availability: A safe, effective vaccine prevents Hepatitis B, yet no vaccine exists for Hepatitis C, making prevention reliant on safe injection practices.
Common decision mistake: Assuming similar liver damage timelines—Hepatitis B may cause cirrhosis in decades, while Hepatitis C can progress faster, especially with alcohol use or co-infection.

Table of Contents18 sections

Difference Between Hepatitis B and C: Comparison Table

Aspect	Hepatitis B	C
Definition	Hepatitis B is a DNA virus from the Hepadnaviridae family.	Hepatitis C is an RNA virus from the Flaviviridae family.
Primary Transmission	Transmitted via blood, semen, and vaginal fluids during sex or birth.	Transmitted mainly through direct blood-to-blood contact with infected needles.
Chronic Infection Rate	Chronic infection develops in fewer than 5% of healthy adults.	Chronic infection develops in approximately 75-85% of infected individuals.
Vaccine Availability	Safe and effective vaccine prevents infection with over 95% efficacy.	No vaccine exists to prevent hepatitis C infection.
Incubation Period	Incubation ranges from 60 to 150 days, averaging 90 days.	Incubation ranges from 14 to 80 days, averaging 45 days.
Acute Symptoms	Acute illness causes jaundice, fatigue, nausea, and abdominal pain in 30-50%.	Acute infection is asymptomatic in 70-80% of cases.
Diagnostic Marker	HBsAg surface antigen confirms active hepatitis B infection.	Anti-HCV antibody test followed by HCV RNA confirms active infection.
Liver Cancer Risk	Chronic HBV causes hepatocellular carcinoma in up to 25% of carriers.	Chronic HCV causes hepatocellular carcinoma in 1-4% per decade.
Treatment Duration	Oral antivirals like tenofovir require daily use for 1-2 years.	Direct-acting antivirals cure infection in 8-12 weeks.
Cure Rate	Functional cure is rare; treatment suppresses viral replication long-term.	Sustained virologic response cures over 95% of patients.
Global Prevalence	Approximately 254 million people live with chronic hepatitis B.	Approximately 50 million people live with chronic hepatitis C.
Mortality Rate	HBV causes about 1.1 million deaths annually worldwide.	HCV causes about 290,000 deaths annually worldwide.
Sexual Transmission	Sexual contact is a common route, especially among unvaccinated adults.	Sexual transmission is rare, accounting for less than 2% of cases.
Mother-to-Child	Perinatal transmission occurs in 90% of births from HBeAg-positive mothers.	Mother-to-child transmission occurs in about 6% of births.
Genotypes	HBV has 10 genotypes labeled A through J with geographic distribution.	HCV has 8 genotypes and 86 confirmed subtypes worldwide.
Co-infection Risk	HBV co-infection with HCV accelerates liver disease progression significantly.	HCV co-infection with HBV leads to more severe fibrosis and cirrhosis.
Fibrosis Progression	Untreated HBV progresses to cirrhosis in 20-30% of chronic cases.	Untreated HCV progresses to cirrhosis in 20-30% within 20-30 years.
Extrahepatic Effects	HBV causes polyarteritis nodosa and glomerulonephritis in some patients.	HCV causes cryoglobulinemia, lichen planus, and insulin resistance.
Testing Window	HBsAg becomes detectable 30-60 days after exposure to HBV.	HCV RNA becomes detectable 1-2 weeks after exposure to HCV.
Reinfection Risk	Recovery from HBV confers lifelong immunity against reinfection.	Recovery from HCV does not confer immunity; reinfection is possible.
Antiviral Classes	HBV uses nucleos(t)ide analogs like entecavir and tenofovir.	HCV uses NS3/4A protease inhibitors and NS5A inhibitors.
Surveillance Need	HBV carriers need lifelong monitoring every 6 months for cancer.	HCV patients need monitoring every 6-12 months after cure if cirrhosis exists.
Occupational Exposure	HBV has 30% transmission risk from needlestick injury.	HCV has 1.8% transmission risk from needlestick injury.
Blood Screening	HBV screening uses nucleic acid testing for blood donations globally.	HCV screening uses anti-HCV and NAT to detect donations.
Public Health Goal	WHO targets HBV elimination by 2030 with vaccination and treatment.	WHO targets HCV elimination by 2030 with cure and harm reduction.
Liver Transplant Need	HBV cirrhosis accounts for 5-10% of liver transplants in Asia.	HCV cirrhosis accounts for 15-20% of liver transplants in the US.
Natural History	HBV has phases: immune tolerant, immune active, and inactive carrier.	HCV has slow progression with fluctuating ALT levels over decades.
Best-Fit Scenario	HBV best fits prevention via universal infant vaccination programs.	HCV best fits cure-focused strategies with direct-acting antiviral therapy.

What Is Hepatitis B?

Hepatitis B is a viral liver infection caused by the hepatitis B virus (HBV), transmitted through blood, semen, or other bodily fluids. It attacks liver cells, causing inflammation that can lead to acute illness or chronic disease, including cirrhosis and liver cancer.

Definition of Hepatitis B

Hepatitis B is a potentially life-threatening liver infection caused by the DNA virus HBV, belonging to the Hepadnaviridae family. The virus replicates within hepatocytes, triggering immune-mediated liver damage. Chronic infection persists when the immune system fails to clear HBV within six months of exposure.

Key Characteristics of Hepatitis B

Characteristic	What It Means in Practice
Transmission route	Spread via percutaneous or mucosal contact with infectious blood, semen, or vaginal fluids; not through casual contact or breastfeeding.
Incubation period	Typically 60-150 days (average 90 days) from exposure to symptom onset, allowing silent spread before diagnosis.
Acute vs chronic	Acute infection resolves within 6 months in 95% of adults; chronic infection persists beyond 6 months in 90% of infected infants.
Vaccine availability	A highly effective 3-dose recombinant vaccine provides 98-100% seroprotection, preventing infection and its complications.
Surface antigen (HBsAg)	Positive HBsAg indicates active infection; persistence beyond 6 months defines chronic hepatitis B.
Liver fibrosis risk	Untreated chronic HBV leads to progressive fibrosis, cirrhosis in 20-30% of cases, and hepatocellular carcinoma.
Antiviral treatment	Oral nucleos(t)ide analogues (tenofovir, entecavir) suppress viral replication but rarely achieve functional cure (HBsAg loss).
Global prevalence	An estimated 254 million people live with chronic HBV worldwide, with highest prevalence in sub-Saharan Africa and East Asia.
Vertical transmission	Mother-to-child transmission at birth accounts for 50% of chronic cases; timely birth-dose vaccine plus hepatitis B immunoglobulin prevents this.
Co-infection risk	HBV co-infection with hepatitis D virus (HDV) accelerates liver damage; HDV requires HBV for replication and worsens prognosis.

Common Examples of Hepatitis B

Acute icteric hepatitis - Sudden onset of jaundice, dark urine, and fatigue; resolves spontaneously in most adults within 4-8 weeks.
Chronic inactive carrier - Persistently positive HBsAg with normal liver enzymes and low viral DNA; requires lifelong monitoring every 6-12 months.
Chronic active hepatitis - Elevated ALT and HBV DNA above 2,000 IU/mL; warrants antiviral therapy to prevent fibrosis progression.
Fulminant hepatitis - Rare severe form causing acute liver failure within weeks; carries 30-50% mortality without urgent transplantation.
Occult hepatitis B - Detectable HBV DNA but negative HBsAg; poses transfusion-transmission risk and reactivation during immunosuppression.
Perinatal infection - Newborn infection from HBeAg-positive mothers; progresses to chronic disease in 70-90% of untreated infants.
Healthcare worker exposure - Needlestick injury from HBsAg-positive source carries 30% infection risk; post-exposure prophylaxis prevents disease.
Hemodialysis-associated HBV - Dialysis patients show higher chronicity rates and lower vaccine response; requires strict infection control protocols.
Immunosuppressed reactivation - Cancer chemotherapy or biologics can reactivate dormant HBV, causing severe hepatitis flares.
HBV-HIV co-infection - Affects 10% of HIV patients globally; accelerates liver fibrosis and requires combined antiretroviral therapy.

Advantages and Limitations of Hepatitis B

Advantages	Limitations
Effective preventive vaccine exists, offering 98-100% protection with 3 doses and durable immunity for at least 30 years.	No curative therapy exists; current antivirals suppress but rarely eliminate the virus, requiring indefinite treatment in most chronic cases.
Routine screening via HBsAg and HBV DNA tests enables early diagnosis and timely intervention before cirrhosis develops.	Vaccine coverage remains low in many low-income regions, with only 42% of infants worldwide receiving the birth dose.
Oral antivirals (tenofovir, entecavir) are highly potent, well-tolerated, and have high genetic barriers to resistance.	Treatment costs and monitoring requirements burden healthcare systems; lifelong therapy can cost $50-500 monthly depending on region.
Vertical transmission is preventable with birth-dose vaccine plus hepatitis B immunoglobulin, achieving 95% prevention efficacy.	Stigma and discrimination persist against HBV carriers in employment and social settings, deterring testing and disclosure.
Clear serological markers (HBsAg, anti-HBs, anti-HBc) allow precise staging of infection and immunity status.	Chronic HBV silently progresses; up to 50% of infected individuals are unaware of their status until advanced liver disease appears.
Antiviral therapy reduces hepatocellular carcinoma risk by 50-60% in patients with cirrhosis, improving long-term survival.	Liver cancer risk persists even after viral suppression, especially in patients with pre-existing cirrhosis or high baseline risk.
Universal infant vaccination programs have reduced chronic HBV prevalence by 90% in endemic countries like Taiwan.	Vaccine non-response occurs in 5-10% of adults, particularly those over 40, obese, smokers, or immunocompromised individuals.
Acute HBV infection in adults resolves spontaneously in 95% of cases, conferring lifelong protective immunity.	Acute infection can rarely progress to fulminant hepatitis, causing acute liver failure with 30-50% mortality without transplant.
Combination therapy with tenofovir and emtricitabine effectively manages HBV-HIV co-infection, treating both viruses simultaneously.	Renal toxicity and bone density loss occur with long-term tenofovir use, requiring periodic renal function and bone monitoring.
Pegylated interferon therapy offers finite 48-week treatment with 10-15% HBsAg loss rates, potentially achieving functional cure.	Interferon causes significant side effects (flu-like symptoms, depression, neutropenia) and is contraindicated in decompensated cirrhosis.

What Is C?

Hepatitis C is a viral liver infection caused by the hepatitis C virus (HCV). It spreads primarily through blood-to-blood contact. Chronic HCV infection can progress silently for decades, leading to cirrhosis, liver failure, or hepatocellular carcinoma. Unlike hepatitis B, HCV has no vaccine, but modern direct-acting antivirals cure over 95% of cases.

Definition of C

Hepatitis C is a single-stranded RNA virus belonging to the Flaviviridae family, genus Hepacivirus. It establishes persistent infection in hepatocytes, evading immune clearance through high mutation rates. The infection is classified as acute (first six months) or chronic (lasting beyond six months). HCV has seven major genotypes, with genotype 1 being most common globally.

Key Characteristics of C

Characteristic	What It Means in Practice
Blood-borne transmission	HCV spreads via shared needles, transfusions before 1992, or contaminated medical equipment; sexual transmission is rare.
Silent progression	Up to 80% of acute infections show no symptoms; chronic disease often remains undetected for 20–30 years.
Chronicity rate	About 55–85% of infected individuals develop chronic HCV, unlike HBV where most adults clear the virus spontaneously.
No preventive vaccine	Unlike hepatitis B, no HCV vaccine exists; prevention relies on harm reduction and safe blood screening.
High mutation rate	HCV's error-prone polymerase generates quasispecies, enabling immune escape and complicating vaccine development.
Curable infection	Direct-acting antivirals (DAAs) achieve sustained virologic response in over 95% of patients, typically within 8–12 weeks.
Liver fibrosis risk	Untreated chronic HCV accelerates fibrosis; cirrhosis develops in 15–30% of chronic cases within 20 years.
Extrahepatic effects	HCV causes cryoglobulinemia, glomerulonephritis, and insulin resistance, affecting organs beyond the liver.
Genotype variability	Seven genotypes and 67 subtypes influence treatment choice; genotype 3 is harder to cure than others.
Global burden	An estimated 58 million people live with chronic HCV worldwide, with 1.5 million new infections annually.

Common Examples of C

Genotype 1a – Most prevalent in North America; responds well to ledipasvir/sofosbuvir regimens.
Genotype 1b – Dominant in Europe and Japan; highly curable with glecaprevir/pibrentasvir.
Genotype 2 – Common in West Africa and Italy; typically easy to cure with sofosbuvir/velpatasvir.
Genotype 3 – Associated with faster fibrosis progression; requires extended therapy or ribavirin addition.
Genotype 4 – Prevalent in Middle East and Egypt; curable with elbasvir/grazoprevir.
Genotype 5 – Mostly found in South Africa; responds well to pan-genotypic DAAs.
Genotype 6 – Common in Southeast Asia; treated effectively with sofosbuvir-based combinations.
Acute HCV infection – First six months post-exposure; 15–45% clear spontaneously without treatment.
Chronic HCV with cirrhosis – Advanced liver scarring; requires monitoring for decompensation and hepatocellular carcinoma.
HCV/HIV coinfection – Affects 2.3 million people globally; accelerates liver disease but remains curable with DAAs.

Advantages and Limitations of C

Advantages	Limitations
Highly curable: over 95% of patients achieve viral clearance with 8–12 weeks of oral DAA therapy.	No vaccine exists, leaving high-risk populations vulnerable to reinfection after cure.
Short treatment duration: most regimens complete in 8–12 weeks, unlike HBV's lifelong therapy.	High drug costs in some regions limit access; generic versions reduce price but not everywhere.
Oral, well-tolerated medications: DAAs have minimal side effects compared to older interferon injections.	Silent progression means many patients are diagnosed late, already at cirrhosis or liver cancer stage.
Pan-genotypic options: drugs like sofosbuvir/velpatasvir work across all seven genotypes without testing.	Reinfection risk persists for people who inject drugs; harm reduction services are essential but underfunded.
Liver function improves after cure: fibrosis can regress, reducing cirrhosis complications over time.	Advanced cirrhosis patients may still develop hepatocellular carcinoma even after viral clearance.
Prevention through blood screening: nucleic acid testing has virtually eliminated transfusion-transmitted HCV.	Acute infection is often asymptomatic, so most new cases go undiagnosed until chronic stage.
Direct-acting antivirals are safe in HIV coinfection, enabling simultaneous management of both viruses.	Treatment failure occurs in 1–5% of cases, particularly with genotype 3 and prior DAA exposure.
WHO elimination targets: HCV is one of few chronic infections earmarked for global elimination by 2030.	Diagnosis requires two-step testing (antibody then RNA), which many low-resource settings cannot complete.
Cure reduces transmission: achieving sustained virologic response eliminates infectiousness to others.	No post-exposure prophylaxis exists; needlestick injuries require monitoring rather than prevention.
Simplified treatment protocols: primary care providers can now prescribe DAAs without specialist referral.	Liver cancer risk persists for decades after cure in patients with pre-existing cirrhosis, requiring lifelong surveillance.

Similarities Between Hepatitis B and C

Shared Aspect	How Hepatitis B and C Are Alike
Liver Target	Both hepatitis B and hepatitis C primarily infect and damage liver cells, leading to inflammation and impaired hepatic function.
Viral Origin	Hepatitis B and hepatitis C are both caused by distinct blood-borne viruses that specifically target the human liver.
Transmission Route	Both hepatitis B and hepatitis C spread through contact with infected blood, sharing needles, or unprotected sex.
Chronic Potential	Both hepatitis B and hepatitis C can progress to chronic infection, persisting in the body for decades without symptoms.
Silent Progression	Both hepatitis B and hepatitis C often remain asymptomatic for years, allowing silent liver damage to accumulate unnoticed.
Diagnostic Blood Test	Both hepatitis B and hepatitis C are diagnosed using specific blood tests that detect viral antigens or antibodies.
Liver Fibrosis Risk	Both hepatitis B and hepatitis C cause progressive liver fibrosis, where scar tissue gradually replaces healthy liver cells.
Cirrhosis Development	Both hepatitis B and hepatitis C can lead to cirrhosis, a severe scarring condition that disrupts liver structure and function.
Hepatocellular Carcinoma	Both hepatitis B and hepatitis C significantly increase the risk of developing hepatocellular carcinoma, the most common liver cancer.
Global Prevalence	Both hepatitis B and hepatitis C affect hundreds of millions of people worldwide, representing major public health burdens.
Prevention Screening	Both hepatitis B and hepatitis C require routine screening in high-risk populations, including healthcare workers and injection drug users.
Maternal Transmission	Both hepatitis B and hepatitis C can be transmitted from mother to baby during childbirth, though rates differ.
Co-infection Risk	Both hepatitis B and hepatitis C can infect the same person simultaneously, complicating treatment and accelerating liver damage.
Antiviral Treatment	Both hepatitis B and hepatitis C are treated with antiviral medications that suppress viral replication and reduce liver inflammation.
Treatment Monitoring	Both hepatitis B and hepatitis C require regular viral load testing and liver function monitoring during therapy.
Liver Enzyme Elevation	Both hepatitis B and hepatitis C cause elevated ALT and AST levels, indicating ongoing hepatocyte injury and inflammation.
Extrahepatic Manifestations	Both hepatitis B and hepatitis C can cause symptoms outside the liver, including joint pain, fatigue, and skin rashes.
Immune Response	Both hepatitis B and hepatitis C trigger an immune response that contributes to liver damage while attempting viral clearance.
Public Health Priority	Both hepatitis B and hepatitis C are targeted by World Health Organization elimination goals for viral hepatitis by 2030.
Needle Safety Measures	Both hepatitis B and hepatitis C are prevented by using sterile needles, safe injection practices, and harm reduction programs.
Blood Donor Screening	Both hepatitis B and hepatitis C are screened in blood donations to prevent transfusion-related transmission.
Chronic Carrier State	Both hepatitis B and hepatitis C can establish a chronic carrier state, where the virus persists and remains transmissible.
Fatigue Symptom	Both hepatitis B and hepatitis C commonly cause persistent fatigue, a hallmark symptom that reduces quality of life.
Jaundice Presentation	Both hepatitis B and hepatitis C can present with jaundice, characterized by yellowing of skin and eyes during acute flares.
Abdominal Discomfort	Both hepatitis B and hepatitis C often cause right upper quadrant abdominal pain or discomfort due to liver enlargement.
Lifelong Management	Both hepatitis B and hepatitis C may require lifelong medical follow-up, even after successful treatment, to monitor for relapse.
Risk Factor Overlap	Both hepatitis B and hepatitis C share risk factors such as incarceration, tattoos with unsterile equipment, and hemodialysis.
Viral Suppression Goal	Both hepatitis B and hepatitis C treatment aims to achieve undetectable viral load, reducing transmission and liver damage.
Liver Transplant Indication	Both hepatitis B and hepatitis C can progress to end-stage liver disease, making liver transplantation a necessary option.
Global Awareness Campaigns	Both hepatitis B and hepatitis C are highlighted in World Hepatitis Day campaigns to promote testing, vaccination, and treatment access.

Hepatitis B or C: Which Should You Choose?

Neither Hepatitis B nor Hepatitis C is a choice, but the deciding variable for management is chronicity risk: Hepatitis B becomes chronic in less than 5% of adults, while Hepatitis C becomes chronic in 75–85% of cases. Your treatment path depends entirely on which virus is confirmed by blood test.

When to Use Hepatitis B

Choose Hepatitis B when you need a preventable vaccine (3-dose series, 95% efficacy) or when managing a chronic infection requiring long-term antiviral suppression (tenofovir or entecavir). It spreads via blood, sex, and childbirth, and chronic cases require lifelong liver cancer surveillance every 6 months.

When to Use C

Choose Hepatitis C when you face a curable infection with direct-acting antivirals (DAAs) achieving 95%+ cure in 8–12 weeks, or when no vaccine exists and prevention relies solely on avoiding shared needles and blood exposure. Chronic C requires fibrosis staging, but successful treatment eliminates the virus and halts liver progression.

Common Misconceptions About Hepatitis B and C

Common Myth	The Reality
"Hepatitis B and C are the same disease."	Hepatitis B is a DNA virus, while hepatitis C is an RNA virus; they differ in transmission, chronicity, and treatment.
"You can get hepatitis C from a cough or sneeze."	Hepatitis C spreads only through blood-to-blood contact, never through respiratory droplets, casual touch, or shared utensils.
"Hepatitis B always becomes a lifelong infection."	Hepatitis B resolves spontaneously in over 95% of infected adults, but chronic infection occurs in most infected infants.
"There is no vaccine for hepatitis C."	Hepatitis C has no preventive vaccine, whereas hepatitis B has an effective vaccine with over 98% seroprotection rates.
"Hepatitis B is only transmitted through sexual contact."	Hepatitis B also spreads via contaminated needles, mother-to-child birth, and sharing razors or toothbrushes with infected blood.
"Hepatitis C cannot be cured."	Hepatitis C is curable in over 95% of cases using direct-acting antiviral medications taken for 8 to 12 weeks.
"You will feel sick immediately after exposure."	Hepatitis B incubation lasts 1-4 months, and hepatitis C incubation lasts 2 weeks to 6 months, often without symptoms.
"Hepatitis B and C both require liver biopsy for diagnosis."	Modern diagnosis uses blood tests for antigens, antibodies, and viral RNA or DNA; liver biopsy is rarely needed today.
"Only intravenous drug users get hepatitis C."	Hepatitis C also affects recipients of unscreened blood transfusions, hemodialysis patients, and healthcare workers from needle sticks.
"Hepatitis B is more dangerous than hepatitis C."	Hepatitis C causes chronic liver disease more frequently (75-85%) than hepatitis B (5-10%), making both equally serious.
"A negative antibody test means you are immune."	Negative hepatitis C antibodies mean no infection, but hepatitis B surface antibodies alone confirm immunity; core antibodies indicate past infection.
"Hepatitis B and C can be transmitted through breast milk."	Neither hepatitis B nor hepatitis C transmits through breast milk; breastfeeding is safe, though cracked nipples may pose a minor risk.
"Once cured of hepatitis C, you cannot get it again."	Hepatitis C cure clears the virus, but you remain susceptible to reinfection through new blood exposures, especially among high-risk groups.
"Hepatitis B carriers always need antiviral medication."	Hepatitis B treatment depends on viral load, liver enzyme levels, and fibrosis stage; many inactive carriers only need regular monitoring.
"Hepatitis C only affects the liver."	Hepatitis C also causes cryoglobulinemia, kidney damage, insulin resistance, and fatigue; it is a systemic inflammatory disease.
"Sharing food or water spreads hepatitis B."	Hepatitis B spreads via blood, semen, and vaginal fluids; it does not spread through food, water, or casual household contact.
"Hepatitis B and C symptoms are always obvious."	Up to 70% of hepatitis C cases and 30% of hepatitis B cases are asymptomatic, leading to silent progression toward cirrhosis.
"Pregnant women with hepatitis B always pass it to babies."	With antiviral therapy and infant vaccination within 12 hours of birth, mother-to-child hepatitis B transmission drops below 5%.
"Hepatitis C requires lifelong treatment."	Hepatitis C treatment is short and finite; most patients achieve sustained virologic response after a single 8-12 week course.
"You can donate blood if you had hepatitis B long ago."	Anyone with a history of hepatitis B or hepatitis C is permanently deferred from blood donation, regardless of recovery or cure.
"Hepatitis B and C both have oral medications only."	Hepatitis C uses oral pills, but hepatitis B often requires injected interferons or long-term oral antivirals like tenofovir or entecavir.
"Natural remedies can cure hepatitis C."	No herbal or dietary supplement has proven efficacy against hepatitis C; only FDA-approved direct-acting antivirals achieve cure.
"Hepatitis B is rare in developed countries."	Hepatitis B affects over 250 million people globally, including 1-2 million in the US, with rising rates among younger adults.
"Hepatitis C always causes jaundice."	Jaundice occurs in only 20-30% of acute hepatitis C infections; most people experience no visible signs during early stages.
"Vaccination for hepatitis B also protects against hepatitis C."	Hepatitis B vaccine provides no protection against hepatitis C; no vaccine exists for hepatitis C, so prevention relies on exposure avoidance.
"Hepatitis B and C patients cannot exercise."	Regular moderate exercise improves liver fat, insulin sensitivity, and energy levels in both hepatitis B and hepatitis C patients.
"A liver transplant cures hepatitis C permanently."	Transplant replaces the damaged liver, but hepatitis C can reinfect the new organ; antiviral therapy before transplant prevents recurrence.
"Hepatitis B and C are both sexually transmitted equally."	Hepatitis B transmits sexually much more efficiently; hepatitis C sexual transmission is rare, occurring mainly in HIV-coinfected men who have sex with men.
"You will know if you have hepatitis from routine blood work."	Standard blood panels do not include hepatitis tests; specific viral serology and PCR tests are required for hepatitis B or C diagnosis.
"Hepatitis B and C both have similar mortality rates."	Hepatitis B kills about 820,000 people yearly, while hepatitis C kills about 290,000; hepatitis B causes more deaths due to higher prevalence.

Conclusion

Difference Between Hepatitis B and C comes down to transmission and chronicity. Hepatitis B spreads through bodily fluids; Hepatitis C spreads primarily through blood. Hepatitis B often resolves acutely, while Hepatitis C becomes chronic in most cases. Choose Hepatitis B vaccination for prevention; choose Hepatitis C screening for early detection and cure.

FAQs on Difference Between Hepatitis B and C

What is the difference between Hepatitis B and Hepatitis C?: Hepatitis B is a DNA virus transmitted through blood, semen, or other body fluids, while Hepatitis C is an RNA virus spread primarily through blood-to-blood contact, with both targeting the liver but differing in chronic infection rates and treatment approaches.
Which is worse, Hepatitis B or Hepatitis C?: Hepatitis C is generally considered more severe in its chronic form because it leads to cirrhosis or liver cancer in up to 25% of infected individuals, whereas Hepatitis B has a higher rate of spontaneous clearance in adults, though both can cause fatal liver damage.
Is Hepatitis C more curable than Hepatitis B?: Yes, Hepatitis C is now curable in over 95% of cases with direct-acting antiviral medications taken for 8-12 weeks, while Hepatitis B has no complete cure and requires long-term antiviral therapy to suppress the virus and prevent liver complications.
What is the cost difference between Hepatitis B and Hepatitis C treatment?: Hepatitis B treatment costs roughly $500 to $2,000 per month for lifelong antiviral pills, whereas Hepatitis C curative therapy ranges from $24,000 to $94,000 for a full course, though generic versions have reduced prices to under $1,000 in some countries.
Which is more contagious, Hepatitis B or Hepatitis C?: Hepatitis B is 50 to 100 times more infectious than Hepatitis C because it survives outside the body for up to seven days and transmits easily through sexual contact, needle sharing, or from mother to baby, whereas Hepatitis C requires direct blood exposure and is rarely sexually transmitted.
Can you have both Hepatitis B and Hepatitis C at the same time?: Yes, co-infection with both Hepatitis B and Hepatitis C occurs in about 5-10% of people with chronic viral hepatitis, and this combination accelerates liver damage, increases cirrhosis risk, and requires careful treatment sequencing to avoid viral reactivation.
Is Hepatitis B or Hepatitis C more common in the United States?: Hepatitis C is more common in the United States, with an estimated 2.4 million people living with chronic infection versus 0.8 to 1.0 million with chronic Hepatitis B, though Hepatitis B rates are higher among Asian-American and immigrant populations.
Can Hepatitis B be treated the same way as Hepatitis C?: No, Hepatitis B requires nucleoside analogs like tenofovir or entecavir to suppress viral replication indefinitely, while Hepatitis C uses interferon-free direct-acting antivirals that eradicate the virus, so the two diseases need completely different medication regimens and monitoring schedules.
What is the survival rate for Hepatitis B compared to Hepatitis C?: Untreated Hepatitis B has a 15-25% risk of dying from cirrhosis or liver cancer over decades, while untreated Hepatitis C carries a similar 15-30% mortality risk, but with modern treatments, Hepatitis C patients achieve normal life expectancy whereas Hepatitis B patients still face ongoing surveillance needs.
Can I switch from Hepatitis B treatment to Hepatitis C treatment?: No, you cannot switch between these treatments because they target different viruses, and using Hepatitis C drugs for Hepatitis B is ineffective, so you must complete your Hepatitis B antiviral regimen and only consider Hepatitis C therapy if you have a confirmed co-infection with that specific virus.